A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

November 1, 2026

Study Completion Date

December 1, 2026

Conditions
Recurrent GlioblastomaRecurrent Gliomas
Interventions
DEVICE

Device :DaRT seeds

The sources are impregnated with a layer containing Ra-224 which is well fixated to the surface of the source. Ra-224 undergoes a series of decay events with each daughter product producing an alpha particle

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

Sponsors
All Listed Sponsors
lead

Alpha Tau Medical LTD.

INDUSTRY